Skip to content

The necessity of routine use of neostigmine to reverse neuromuscular block in pediatric patients

The necessity of routine use of neostigmine to reverse neuromuscular block in pediatric patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012890
Enrollment
Unknown
Registered
2017-10-05
Start date
2017-11-01
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Residual neuromuscular block

Interventions

experimental group:routine use of neostigmine
control group:use of neostigmine under neuromuscular monitor

Sponsors

West China Hospital, Sichuan Universtiy
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 12 Years

Inclusion criteria

Inclusion criteria: 1. ASA I-II; 2. Hernia repair patients aged 3 months to 12 years old; 3. Use of neuromuscular block agents during operation.

Exclusion criteria

Exclusion criteria: Patients with neuromuscular junction disease, cardiovascular disease, respiratory disease and hepatic disease; Use of any drugs may interfere the funcion of neuromuscular junction within 3 months.

Design outcomes

Primary

MeasureTime frame
the incidence of residual neuromuscular block;the incidence of neostigmine induced muscle paraysis;

Secondary

MeasureTime frame
the time between the end of operation and extuation;the time between the end of operation and patient transferred out of OR;the length of stay in PACU;the incidence of hypoxia during PACU stay;the number of patients need assisted ventilation during PACU stay;adverse events related to the use of neostigmine;

Countries

China

Contacts

Public ContactYunxia Zuo

West China Hospital, Sichuan Universtiy

zuoyunxiahxa@qq.com+86 18980601541

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026